Peptides, Proximity, and Precision: The Expanding Druggable Proteome
Drug discovery is ever-evolving with simultaneous advances in modality, mechanism, and druggable landscape. The assets entering the clinic in 2025 mark a genuine striking point across multiple fronts. A modality once confined to injectables is routinely going oral, expanding opportunities to indications long reserved for biologics. Induced-proximity and ternary complex-stabilization mechanisms have progressed from preclinical concepts to established pipeline strategies, disarming targets that resisted decades of pursuit via traditional approaches. Mature target classes are yielding first- and best-in-class assets as advances in selectivity, binding kinetics, and molecule design catch up to the underlying biology. And the oldest drug target family is having a second act, with structure-enabled design unlocking therapeutic opportunities few expected to unfold. This talk highlights ten recent programs across macrocyclic peptides, Class B GPCRs, functionally-differentiated small molecules, and proximity pharmacology, highlighting the chemical matter, target biology, and design strategies that distinguish them and what insights/lessons discovery teams can leverage.
Hosted by:
